Leadership team

Our team brings together management excellence, experienced industry profiles and world-class scientific expertise.

Management team

Bernard Pau, PhD

Chairman & Acting CSO

Hon. Professor, Immunology, U-Montpellier. Former Head of the Department of Life Sciences CNRS, Paris. Director, entrepreneur, expert in the development of Biotech & Pharma innovation.

Sylvain Yon, PhD

CEO

20 years’ experience in medical devices and biotechnology startups. Sylvain is an active business angel and strategic consultant for some very promising ventures in healthcare. He holds an engineering degree from ESPCI ParisTech and a PhD from Paris Diderot University.

Maxime Waldron

CFO

Investment banking background (M&A and ECM) and Finance Lecturer at Sorbonne University

Anne Chevrel, PhD. M. Eng

Head of Discovery & Technology

More than 10 years of experience in protein engineering and discovery in biopharma companies.

Johanna Marines, PharmD. PhD. M. Eng

Head of Preclinical

PharmD. from Montpellier University & Engineer from l’Ecole des Mines Albi. PhD in Cancer Biology focused on tumor microenvironment.

Cécile Durand

Business Development Director

20 years’ experience in international business development for innovation-driven CROs and start-ups in the biopharmaceutical industry. She holds a MS in Biochemistry.

Medical advisory board

The company has established a Medical Advisory Board to enhance its ability to identify and select innovative targets. This board comprises international experts in clinical medicine, pharmacology, and pharmaceutical development. The primary purpose of this advisory board is to provide strategic guidance on future product positioning.

Pr Jean-Yves Blay, MD, PhD

Medical Oncologist & Executive Director Centre Léon Bérard at Cancer Research Center of Lyon (CRCL, France)
Sarcomas, Oncology, Clinical trials

Pr Karim Fizazi, MD, PhD

Medical Oncologist at Institut Gustave Roussy
Prostate cancer, Oncology, Clinical trials

Dr Diego Tosi, MD PhD

Medical Oncologist, Head of the Montpellier Cancer Institute (ICM) Early Clinical Phases Unit

Pr Guillaume Cartron, MD PhD

Head of the Hematology Department of Montpellier University Hospital

Pr Hervé Watier, MD PhD

Director of MabImprove Labex Immunology U-Tours

Dr Thierry Chardès, PharmD PhD

Pharmacist and Doctor of Sciences. Research director at CNRS, Montpellier

Key advisors

Jean-François Prost, MD

Acting CMO

30 years R&D top management (Servier, Pierre Fabre, UCB Pharma, LFB…).

Contributive to 5 EMA and 4 FDA approvals.

Gordon Waldron

Advisor, Finance & BD

25 years’ experience working as CFO for start-ups primarily in the biotech sector.

Raised > €200 million from international investor base and €50 million via IPO.

Negotiated the sale of Novexel for $500 million.

Pierre Martineau, PhD

Advisor & SAB Member

Engineer Polytechnique school. PhD at Biotechnology Department, Institut Pasteur, Paris (Prof. M. Hofnung).

PostDoc at Cambridge (UK) Center for Protein Engineering (Sir G. Winter).

Team leader Inserm (IRCM, Montpellier).

Deputy Director, IRCM.

Bruno Robert, PhD

Advisor & SAB Member

PhD at University Montpellier (Dr. A. Pelegrin)

PostDoc at University of Lausanne (CH), Department of Biochemistry (Prof. J-P. Mach)

Inserm Scientist (IRCM, Montpellier)